semaglutide super responder A) Maximum weight loss (%) among high responders and responders GLP-1 NEWS: 3x More Weight

Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention

This study was an observational cohort investigation using electronic health record data from the United States Department of Veterans Affairs and included 606,434 patients with type 2 diabetes who newly started either a GLP-1 medication or, as a comparator, a sodium-glucose cotransporter-2 inhibitor (a type 2 diabetes medication that doesnt affect appetite and reward pathways) based on filled outpatient pharmacy records

Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration

Shave or trim underarm hair

This is nutrition education, not medical or medication advice

Unlike an anonymous online purchase or a supplement from a health food store, our process is built on a foundation of care, safety, and science